News

Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.

Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o

Moby summary of Pfizer Inc.'s Q2 2026 earnings call

The quarter exposed where Pfizer's recovery is really coming from

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

Pfizer faces $17 billion patent cliff as investors brace for earnings

Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect.

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

There is more to this stock than meets the eye.

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.

Inspectors issue stop-work order at planned 32-story apartment tower in Manhattan, carrying out safety sweeps after former Pfizer headquarters building buckled.

(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single

(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single

(Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began. Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to Companies, Echoing a 17th Century KingSpaceX Set to Unlock $116 Billion in Shares After IPO Restrictions LiftKrem

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

The former Pfizer headquarters in Midtown has continued to move since emergency responders arrived, officials said Tuesday.

A high-rise building in Manhattan was at risk of collapse after columns buckled and floors sagged, officials said Tuesday, prompting an emergency response during the rush-hour commute. Fire officials said they received a report that bricks were falling from the 38-story building, in the city’s midtown district just before 8 a.m. Officials determined that two columns had buckled on the building’s 21st and 22nd floors and that several floors near the columns were sagging. No injuries were reported, fire officials said.

Could this be the secret to Pfizer's rebound strategy?

(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO